Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease

Published on Aug 1, 2014in Clinical Gastroenterology and Hepatology11.382
· DOI :10.1016/J.CGH.2014.02.016
Nicolas Williet17
Estimated H-index: 17
(Nancy-Université),
William J. Sandborn184
Estimated H-index: 184
(UCSD: University of California, San Diego),
Laurent Peyrin Biroulet12
Estimated H-index: 12
(Nancy-Université)
Sources
Abstract
The Food and Drug Administration (FDA) is moving from the Crohn's Disease Activity Index to patient-reported outcomes (PROs) and objective measures of disease, such as findings from endoscopy. PROs will become an important aspect of assessing activity of inflammatory bowel disease (IBD) and for labeling specific drugs for this disease. PROs always have been considered in the management of patients with rheumatoid arthritis or multiple sclerosis, and have included measurements of quality of life, disability, or fatigue. Several disease-specific scales have been developed to assess these PROs and commonly are used in clinical trials. Outcomes reported by patients in clinical trials of IBD initially focused on quality of life, measured by the Short-Form 36 questionnaire or disease-specific scales such as the Inflammatory Bowel Disease Questionnaire or its shorter version. Recently considered factors include fatigue, depression and anxiety, and work productivity, as measured by the Functional Assessment Chronic Illness Therapy-Fatigue, the Hospital Anxiety Depression, and the Work Productivity Activity Impairment Questionnaire, respectively. However, few data are available on how treatment affects these factors in patients with IBD. Although disability generally is recognized in patients with IBD, it is not measured. The international IBD disability index currently is being validated. None of the PROs currently used in IBD were developed according to FDA guidance for PRO development. PROs will be a major primary end point of future trials. FDA guidance is needed to develop additional PROs for IBD that can be incorporated into trials, to better compare patients' experience with different therapies.
📖 Papers frequently viewed together
References147
Newest
#1Mike van der Have (UU: Utrecht University)H-Index: 11
#2Karen S. van der Aalst (UU: Utrecht University)H-Index: 2
Last. Herma H. Fidder (UU: Utrecht University)H-Index: 27
view all 7 authors...
Background and aims: Understanding the determinants of Crohn's disease (CD) patients' health-related quality of life (HRQOL) may facilitate interventions that improve HRQOL. Therefore, we systematically assessed determinants of HRQOL in adult CD patients. Methods: The databases PubMed, EMBASE, the Cochrane Library, PsycINFO and CINAHL were searched for English abstracts, related to socio-demographic, psychological, clinical and treatment-related determinants of HRQOL in CD disease. Two independe...
Source
#5Richard S. Strauss (Janssen Pharmaceutica)H-Index: 30
Background & Aims Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-α (TNFα), was evaluated as maintenance therapy in TNFα antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy. Methods We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, e...
Source
#7Josef Smolen (Medical University of Vienna)H-Index: 8
Abstract Background and aims Busy clinical settings often restrict the possibility to focus on concepts that determine health in a positive way, commonly assessed by using patient-reported outcomes (PROs). We aimed to explore which determinants of health (DHs) are important to people with Crohn's disease (CD), to understand possible gender differences and to analyze whether these DHs are covered by PROs used in CD. Methods Two systematic literature reviews were done to identify relevant DHs and ...
Source
#1Ruben A. Mesa (Mayo Clinic)H-Index: 91
#2Alan L. Shields (Adelphi University)H-Index: 18
Last. Srdan Verstovsek (University of Texas MD Anderson Cancer Center)H-Index: 114
view all 9 authors...
Abstract Patient-reported outcomes (PROs) and spleen size in patients not receiving therapy ( N = 154) in COMFORT-I, a randomized, double-blind study of the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis were evaluated. Baseline PROs indicated considerable disease burden. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores, modified Myelofibrosis Symptom Assessment Form v2.0 Total Symptom Score, and P...
Source
#1Ashwin N. Ananthakrishnan (Harvard University)H-Index: 78
#2Millie D. Long (UNC: University of North Carolina at Chapel Hill)H-Index: 35
Last. Michael D. Kappelman (UNC: University of North Carolina at Chapel Hill)H-Index: 50
view all 5 authors...
BACKGROUND & AIMS: Impairment of sleep quality is common in patients with inflammatory bowel diseases (IBDs) (eg, Crohn’s disease [CD] and ulcerative colitis [UC]), even during clinical remission. Sleep impairment can activate inflammatory pathways. Few prospective studies have examined the role of sleep disturbance on risk of relapse in IBD. METHODS: We analyzed data from 3173 patients with IBD (1798 in clinical remission at baseline) participating in the Crohn’s and Colitis Foundation of Ameri...
Source
#1Clarence K. Zhang (Yale University)H-Index: 17
#2Jennifer Hewett (RAFAEL: Rafael Advanced Defense Systems)H-Index: 1
Last. Deborah D. Proctor (Yale University)H-Index: 25
view all 10 authors...
Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract that significantly impacts the health-related quality of life (HR-QOL). A decreased HR-QOL has been demonstrated in patients with active disease compared with patients in remission. In this cross-sectional study, we examined the role of depression and disease activity as independent factors in predicting patient's HR-QOL.Hundred and five patients with either Crohn's disease (CD) or ulcerative colitis (UC)...
Source
#1Claire N. Harrison (Guy's and St Thomas' NHS Foundation Trust)H-Index: 74
#2Ruben A. Mesa (Mayo Clinic)H-Index: 91
Last. Alessandro M. Vannucchi (UniFI: University of Florence)H-Index: 105
view all 18 authors...
Patients with myelofibrosis (MF) have significant debilitating symptoms, physical disabilities, and poor health-related quality of life (HRQoL). Here, we report post-hoc analyses of the impact of ruxolitinib, a potent and selective JAK1 and JAK2 inhibitor, on disease-related symptoms and HRQoL in MF patients from the large phase 3 COMFORT-II study (N = 219). During the follow-up period of 48 weeks, HRQoL and MF-associated symptoms improved from baseline for ruxolitinib-treated patients but remai...
Source
#1Maura Corsetti (Katholieke Universiteit Leuven)H-Index: 26
#2Jan Tack (Katholieke Universiteit Leuven)H-Index: 128
Trial design and endpoints for the evaluation of drug efficacy in irritable bowel syndrome (IBS) underwent major changes over the last two decades. A systematic review in the early 1990s concluded that there were few well-designed and well-executed treatment trials in IBS. Over the next decade, the so-called binary endpoints were used in several clinical trials in IBS in the US, Europe and other parts of the world. In 2006, the Food and Drug Administration (FDA) published a general guidance for ...
Source
#1Karel Pavelka (Charles University in Prague)H-Index: 78
#2Zoltán Szekanecz (University of Debrecen)H-Index: 73
Last. Radu Vasilescu (Pfizer)H-Index: 6
view all 14 authors...
Biologics have mainly been assessed in patients with severe rheumatoid arthritis (RA) globally. Less attention has been paid to moderately active disease, especially in Central and Eastern Europe (CEE). Access to biologics and the disease features of RA patients may differ in CEE, relative to other regions. We assessed the clinical and patient-reported outcomes (PROs) of treatment from CEE patients in the multinational PRESERVE study (NCT00565409). Patients with moderate RA 28-joint disease acti...
Source
#1Ute Krügel (Leipzig University)H-Index: 31
#2Johannes Fischer (Leipzig University)H-Index: 3
Last. Hubertus Himmerich (Leipzig University)H-Index: 38
view all 5 authors...
Abstract Pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) have repeatedly been shown to play a pivotal role in the pathophysiology of depression. Therefore, we tested the possible antidepressant-like effect of the anti-TNF-α drug etanercept in an animal model of chronic mild stress. Male Wistar rats were assigned to a non-restrained and a restrained protocol for 5 weeks. From beginning of the third week the animals were treated either with Ringer solution daily or with eta...
Source
Cited By165
Newest
Crohn’s disease (CD) is a chronic disorder characterized by full thickness patchy inflammation of the gastrointestinal tract. The pathogenesis is multifactorial and involves defective innate immune responses, microbiome alterations, and dysregulated activation of the acquired component of mucosal immunity. One of the molecular mediators that is involved at different levels in the initiation and progression of intestinal inflammation characteristic of CD is tumor necrosis factor (TNF). The presen...
Source
#1Lasse R. Lundquist (University of Southern Denmark)
#2Bjorn Rasmussen (University of Southern Denmark)H-Index: 2
Last. Peter Haastrup (University of Southern Denmark)H-Index: 9
view all 6 authors...
Health-related quality of life (HRQoL) is impaired in patients with Crohn’s disease (CD). This study aimed to identify the impact of clinical disease activity on HRQoL in CD patients treated with b...
Source
#1Amy GrantH-Index: 10
#2Trudy LererH-Index: 30
Last. Anthony R. OtleyH-Index: 36
view all 5 authors...
Source
#1Jessica K. Salwen-Deremer (Dartmouth–Hitchcock Medical Center)H-Index: 3
#2Michael T. Smith (Johns Hopkins University)H-Index: 60
Last. Corey A. Siegel (Dartmouth–Hitchcock Medical Center)H-Index: 51
view all 5 authors...
Poor sleep is common in inflammatory bowel disease (IBD), predicting increased risk of flares, surgery, and/or hospitalization and reducing quality of life. To profile specific sleep disorder symptoms in IBD, informing intervention efforts. 312 adults with Crohn’s disease or ulcerative colitis were recruited from an academic medical center in New Hampshire, USA. Participants completed online surveys about sleep including well-validated measures of sleep quality, insomnia, restless leg syndrome, ...
Source
25 years ago the field was revolutionized by the introduction of infliximab as the first hybrid anti-TNF-antibody. Subsequently, other humanized anti-TNFs were developed and marketed, followed by antibodies to new targets including integrins (vedolizumab) and interleukin (IL) 12/23 (ustekinumab). All these so-called biologicals were shown in registrational trials to induce remission superior to placebo but consistently were effective in only a minority of patients. Even though in most trials onl...
Source
(1) Background: Stress, anxiety, and depression have been identified as factors that influence the development of inflammatory bowel disease (IBD). The main aim of this study was to test the effectiveness of group multicomponent cognitive-behavioral therapy at reducing stress, anxiety, and depression, and improving quality of life and the clinical course of the disease. (2) Methods: A total of 120 patients were evaluated using the General Perceived Stress Scale, Scale of Stress Perceived by the ...
Source
#1Ioannis Varbobitis (University of Nottingham)H-Index: 1
#2G Kokkotis (UoA: National and Kapodistrian University of Athens)H-Index: 1
Last. Giorgos Bamias (UoA: National and Kapodistrian University of Athens)H-Index: 35
view all 14 authors...
BACKGROUND Fatigue is highly prevalent among patients with inflammatory bowel disease (IBD) and may have an unfavorable impact on quality of life (QoL). The IBD-Fatigue scale (with components SCORE1 and SCORE2) is a recently developed disease-specific questionnaire. We sought to validate a Greek version of IBD-F and use it to assess the severity and characteristics of fatigue and its effect on QoL in our study population. METHODS The IBD-F scale was validated and used to obtain fatigue-related d...
Source
#1S. TadbiriH-Index: 3
#2Maria NachuryH-Index: 19
Last. Aurelien AmiotH-Index: 27
view all 32 authors...
BACKGROUND AND AIM The inflammatory bowel disease [IBD]-disk is a 10-item self-questionnaire that is used to assess IBD-related disability. The aim of the present study was to evaluate this tool in the assessment of IBD daily-life burden. METHODS A 1-week cross-sectional study was conducted in 42 centres affiliated in France and Belgium. Patients were asked to complete the IBD-disk [best score: 0, worst score: 100] and a visual analogue scale [VAS] of IBD daily-life burden [best score: 0, worst ...
Source
#1Chiara Conti (University of Chieti-Pescara)H-Index: 23
#2Ilenia Rosa (Sapienza University of Rome)H-Index: 2
Last. Piero Porcelli (University of Chieti-Pescara)H-Index: 30
view all 7 authors...
Objective: The present preliminary cross-sectional study aimed to investigate the extent to which health-related quality of life of patients with inflammatory bowel disease (IBD) was influenced by the outbreak of Covid-19 while controlling for disease activity. Methods: Two samples of 195 (recruited before Covid-19 outbreak) and 707 patients (recruited during the Covid-19-related lockdown) were included. Psychological distress (Hospital Anxiety and Depression Scale, HADS), quality of life (Infla...
Source
#1Laurent Peyrin-Biroulet (University of Lorraine)H-Index: 105
#2Edouard LouisH-Index: 87
Last. Subrata Ghosh (University of Birmingham)H-Index: 89
view all 7 authors...
INTRODUCTION In the phase 2 CELEST study, positive efficacy results were obtained with the Janus kinase 1 inhibitor upadacitinib for adult patients with moderate to severe Crohn's disease. We present the health-related quality of life and work productivity improvement results with upadacitinib from CELEST. METHODS CELEST (NCT02365649) was a double-blind study where patients were randomized 1:1:1:1:1:1 in the 16-week induction period to placebo or upadacitinib 3 mg twice daily (BID), 6 mg BID, 12...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.